Michael Dudley, CEO, Co-Founder of Xelcis Bio Inc., shared a post on LinkedIn:
“I am excited to announce that Sendurai Mani has joined Xelcis Bio as a Scientific Advisor!
Dr. Mani serves as a Professor of Pathology and Laboratory Medicine, along with a Professorship of Medicine at Brown University. He also fulfills the role of Associate Director for Translational Oncology at the Legorreta Cancer Center.
His expertise is directly aligned with our mission—TDOX-62 uses our TRIDENT™ platform to precisely target therapeutic delivery to tumor sites, dramatically reducing systemic toxicity while overcoming drug resistance. Dr. Mani’s decades of research, including his previous role as Co-Director of the Metastasis Research Center at MD Anderson Cancer Center, give him unique insights into the biology of treatment-resistant cancers.
His deep understanding of translational medicine is precisely what we need as we advance TDOX-62 toward the clinic. Dr. Mani’s perspective on how laboratory discoveries become life-changing therapies will help us navigate the critical transition from preclinical success to clinical impact.
Welcome to the team, Dr. Mani!”
Sendurai Mani, Associate Director of Translational Oncology, Dean’s Chair of Translational Oncology, and Professor of Medicine at Brown University, and Co-Founder and CSO of Iylon Precision Oncology, shared a post by Michael Dudley, adding:
“Thank you, R. Michael Dudley and the Xelcis Bio Inc. Team for the warm welcome and for the opportunity to serve as a Scientific Advisor. I am excited to contribute to the innovative efforts behind TDOX-62 and to support the impactful science and translational research at Xelcis Bio.”